Science & Platform
Boosting T cell responses directly in the tumor microenvironment
T cells need two signals: tumor targeting as the ignition and costimulation as boost. TWYCE delivers the boost where it is missing: in the tumor microenvironment.
Our science starts where existing immuno-oncology therapies fall short.
Overcoming the limitations of cancer immunotherapy
Immunotherapy has transformed cancer treatment, yet durable responses in solid tumors remain challenging. Limited tumor specificity, off-tumor toxicity and an immunosuppressive tumor microenvironment continue to restrict efficacy and dosing.
TWYCE enables the next level of T cell activation.
Effective T cell responses require two signals: tumor recognition via the T cell receptor (TCR/CD3) and a second, costimulatory signal. While tumors can trigger the first, the second is often missing or insufficient.
TWYCE brings both signals together, directing costimulation to the tumor microenvironment to drive a more specific and sustained anti-tumor immune response.
Our BiCo platform is built around three principles:
Full-blown T cell activity
Combining tumor targeting with TME-anchored CD28 costimulation for a powerful, sustained T cell response.
Specificity
Targeting tumor-associated antigen combinations that are not co-expressed on healthy tissue.
Multiplexed TME platform
One costimulatory backbone can be paired with different tumor-targeting approaches, supporting both TWYCE and partner programs.
Two sites. One coordinated anti-tumor immune response.
A full T cell response requires two coordinated signals. TWYCE brings them together across distinct sites in the TME, combining tumor targeting with locally anchored costimulation where immune activation is otherwise suppressed.

Signal 1: Ignition
Target the tumor: a CD3 TCE, peptide vaccine or partner molecule tells T cells what to attack.

Signal 2: Boost
Sustain the response: our BiCo delivers the CD28 signal at the TME, where immune activation is otherwise suppressed.

Signal 1 + 2: Tumor elimination
A sustained response: with both signals present, T cells expand at the tumor site and stay engaged, achieving durable tumor cell killing and long-lasting immunity.
TME-anchored CD28 costimulation can foster multiple Signal 1 approaches.
The platform of TWYCE builds upon a unique approach: two compartments, two signals. Signal 1 targets the tumor cell and directs T cells to what they should attack; Signal 2 provides CD28 costimulation at the surrounding immunosuppressive stroma. Our BiCos deliver Signal 2 by binding CD28 and a target in the TME, such as FAP in our lead program. They are paired with own CD3 TCEs and cancer vaccines, but are also available for partner-provided Signal 1 programs.

BiCos in combination with TCEs
Signal 1 and Signal 2 are delivered by TCEs targeting the tumor and TME-anchored BiCos. Full T cell activation occurs only when both bispecifics have bound their respective targets, which allows for largely increased specificity, reduced toxicity and sustained efficiency.

BiCos in combination with cancer vaccines
Cancer vaccines induce tumor-specific T cells enabling targeting of intracellular antigens; BiCos boost the T cells within the TME where they are usually suppressed, which allows for the expansion required to combat high tumor burden and sustains efficacy.
Signal 1
Ignition by tumor targeting
Signal 2
Boost by targeting TME
One BiCo, multiple combinations
Our BiCos can provide the missing Signal 2 for multiple Signal 1 approaches: partners can pair their own TCEs or vaccines with our TME-anchored BiCos to add the missing costimulation.
Selected publications
- Publication Bivalent bispecific CD28 antibodies reinforce T cell responsiveness and revert anergy/quiescence in patients treated with bispecific CD3 antibodies The description of our optimized BiCo constructs: first ex vivo proof that our bivalent CD28 antibodies with optimized function restore and boost responsiveness of T cells that have become exhausted upon treatment with CD3 TCEs.
- Publication An optimized IgG-based B7-H3×CD3 bispecific antibody for treatment of gastrointestinal cancers The introduction of CC-3: tuning both the B7-H3 epitope and CD3 affinity enabled generation of a TCE with improved tumor cell killing and memory formation, despite reduced cytokine release.
- Publication An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer The introduction of CC-1: a PSMA×CD3 bispecific in an IgG-based format that reaches both prostate carcinoma cells and the tumor vasculature, with first observations in treated patients.